Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vascular Disease
Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
July 22nd, 2007
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported results from preclinical research demonstrating that antibodies directed to a potential new target, angiopoietin-like protein 4 (ANGPTL4), rapidly lower triglycerides and cholesterol. Research suggests that a monoclonal antibody (mAb) targeting ANGPTL4 may have therapeutic application in the treatment of cardiovascular disease. The results appeared in an article, entitled "Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice," published in the July 10, 2007 edition of the journal Proceedings of the National Academy of Sciences. Lexicon...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
